SE9803871D0 - Therapeutic method and formulation - Google Patents

Therapeutic method and formulation

Info

Publication number
SE9803871D0
SE9803871D0 SE9803871A SE9803871A SE9803871D0 SE 9803871 D0 SE9803871 D0 SE 9803871D0 SE 9803871 A SE9803871 A SE 9803871A SE 9803871 A SE9803871 A SE 9803871A SE 9803871 D0 SE9803871 D0 SE 9803871D0
Authority
SE
Sweden
Prior art keywords
layer
controlled release
formulation
water
therapeutic method
Prior art date
Application number
SE9803871A
Other languages
English (en)
Swedish (sv)
Inventor
Lisbeth Nilvebrant
Bengt Hallen
Birgitta Olsson
Jan Stroembom
Original Assignee
Pharmacia & Upjohn Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20413266&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE9803871(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia & Upjohn Ab filed Critical Pharmacia & Upjohn Ab
Priority to SE9803871A priority Critical patent/SE9803871D0/xx
Publication of SE9803871D0 publication Critical patent/SE9803871D0/xx
Priority to UA2000052950A priority patent/UA72882C2/uk
Priority to DK99946521.4T priority patent/DK1039882T3/da
Priority to AU58918/99A priority patent/AU745190B2/en
Priority to EA200000468A priority patent/EA002720B1/ru
Priority to IDP20001006A priority patent/ID25824A/id
Priority to CA2311755A priority patent/CA2311755C/en
Priority to SI9931050T priority patent/SI1039882T1/sl
Priority to MEP-2001-331A priority patent/ME00850B/me
Priority to CNB99801916XA priority patent/CN1239152C/zh
Priority to PT99946521T priority patent/PT1039882E/pt
Priority to PCT/SE1999/001463 priority patent/WO2000012069A1/en
Priority to EP99946521A priority patent/EP1039882B1/de
Priority to US09/582,498 priority patent/US6770295B1/en
Priority to GE3951A priority patent/GEP20043354B/en
Priority to APAP/P/2000/001823A priority patent/AP1529A/en
Priority to OA1200000309A priority patent/OA11636A/en
Priority to SK749-2000A priority patent/SK287111B6/sk
Priority to MYPI99003665A priority patent/MY127946A/en
Priority to CZ20001924A priority patent/CZ302630B6/cs
Priority to IL15641499A priority patent/IL156414A0/xx
Priority to NZ504618A priority patent/NZ504618A/xx
Priority to AT99946521T priority patent/ATE487471T1/de
Priority to HU0100437A priority patent/HUP0100437A3/hu
Priority to IL13629499A priority patent/IL136294A/en
Priority to ARP990104280A priority patent/AR029311A1/es
Priority to EP09173927A priority patent/EP2153825A1/de
Priority to TR2000/01998T priority patent/TR200001998T1/xx
Priority to DE69942928T priority patent/DE69942928D1/de
Priority to APAP/P/2001/002166A priority patent/AP1323A/en
Priority to SI9930411T priority patent/SI1128819T1/xx
Priority to BRPI9915142A priority patent/BRPI9915142B8/pt
Priority to CZ20011627A priority patent/CZ299582B6/cs
Priority to KR10-2001-7005879A priority patent/KR100467384B1/ko
Priority to EP99971702A priority patent/EP1128819B1/de
Priority to YUP-331/01A priority patent/RS49891B/sr
Priority to DE69910604T priority patent/DE69910604T2/de
Priority to CA002350061A priority patent/CA2350061C/en
Priority to EEP200100254A priority patent/EE05232B1/xx
Priority to GEAP19995939A priority patent/GEP20022833B/en
Priority to ES99971702T priority patent/ES2204193T3/es
Priority to SK625-2001A priority patent/SK284758B6/sk
Priority to PL99348612A priority patent/PL195780B1/pl
Priority to IL14280999A priority patent/IL142809A0/xx
Priority to OA1200100112A priority patent/OA11673A/en
Priority to EA200100538A priority patent/EA005074B1/ru
Priority to UA2001042824A priority patent/UA57165C2/uk
Priority to CNB998132160A priority patent/CN1169522C/zh
Priority to NZ511430A priority patent/NZ511430A/en
Priority to AU14366/00A priority patent/AU762410B2/en
Priority to MYPI99004911A priority patent/MY122195A/en
Priority to AT99971702T priority patent/ATE247458T1/de
Priority to ARP990105734A priority patent/AR027815A1/es
Priority to PCT/SE1999/002052 priority patent/WO2000027364A1/en
Priority to PT99971702T priority patent/PT1128819E/pt
Priority to US09/763,281 priority patent/US6911217B1/en
Priority to DK99971702T priority patent/DK1128819T3/da
Priority to HU0105038A priority patent/HU226582B1/hu
Priority to JP2000580595A priority patent/JP3616011B2/ja
Priority to IDW00200101038A priority patent/ID30039A/id
Priority to TW089102338A priority patent/TWI222879B/zh
Priority to TW089102332A priority patent/TWI267385B/zh
Priority to BG104476A priority patent/BG65168B1/bg
Priority to NO20002977A priority patent/NO329830B1/no
Priority to IS5537A priority patent/IS2976B/is
Priority to ZA200103575A priority patent/ZA200103575B/en
Priority to IS5936A priority patent/IS2370B/is
Priority to NO20012314A priority patent/NO331399B1/no
Priority to HR20010333A priority patent/HRP20010333B1/xx
Priority to BG105582A priority patent/BG65149B1/bg
Priority to MA26228A priority patent/MA25325A1/fr
Priority to HK01104868A priority patent/HK1034664A1/xx
Priority to HK02102521.2A priority patent/HK1040917B/zh
Priority to CY20101101027T priority patent/CY1111088T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SE9803871A 1998-08-27 1998-11-11 Therapeutic method and formulation SE9803871D0 (sv)

Priority Applications (74)

Application Number Priority Date Filing Date Title
SE9803871A SE9803871D0 (sv) 1998-11-11 1998-11-11 Therapeutic method and formulation
UA2000052950A UA72882C2 (uk) 1998-08-27 1999-08-26 Спосіб лікування нестабільності чи надактивності сечового міхура, фармацевтична композиція з регульованим вивільненням та використання толтеродину
DK99946521.4T DK1039882T3 (da) 1998-08-27 1999-08-26 Terapeutisk formulering til indgivelse af tolterodin med kontrolleret frigivelse
AU58918/99A AU745190B2 (en) 1998-08-27 1999-08-26 Therapeutic formulation for administering tolterodine with controlled release
EA200000468A EA002720B1 (ru) 1998-08-27 1999-08-26 Терапевтическая композиция для введения толтеродина с контролируемым высвобождением и способ лечения мочевого пузыря с её использованием
IDP20001006A ID25824A (id) 1998-08-27 1999-08-26 Formulasi terapeutik untuk memberikan tolterodin dengan pelepasan yang terkendali
CA2311755A CA2311755C (en) 1998-08-27 1999-08-26 Therapeutic formulation for administering tolterodine with controlled release
SI9931050T SI1039882T1 (sl) 1998-08-27 1999-08-26 Terapevtska formulacija za dajanje tolterodina s kontroliranim sproščanjem
MEP-2001-331A ME00850B (me) 1998-08-27 1999-08-26 Nove perle sa kontrolisanim oslobađanjem, postupak za njihovu proizvodnju i višestruka jedinična formulacija koja ih sadrži
CNB99801916XA CN1239152C (zh) 1998-08-27 1999-08-26 控释给药托耳替罗地的治疗制剂
PT99946521T PT1039882E (pt) 1998-08-27 1999-08-26 Formulação terapêutica para administrar tolterodina com libertação controlada
PCT/SE1999/001463 WO2000012069A1 (en) 1998-08-27 1999-08-26 Therapeutic formulation for administering tolterodine with controlled release
EP99946521A EP1039882B1 (de) 1998-08-27 1999-08-26 Therapeutische formulierung zur verabreichung von tolterodin mit kontrollierter freisetzung
US09/582,498 US6770295B1 (en) 1998-08-27 1999-08-26 Therapeutic formulation for administering tolterodine with controlled release
GE3951A GEP20043354B (en) 1998-08-27 1999-08-26 Therapeutic Formulation for Administering Tolterodine with Controlled Release
APAP/P/2000/001823A AP1529A (en) 1998-08-27 1999-08-26 Therapeutic formulation for administering tolterodine with controlled release.
OA1200000309A OA11636A (en) 1998-08-27 1999-08-26 Therapeutic formulation for administering tolterodine with controlled release.
SK749-2000A SK287111B6 (sk) 1998-08-27 1999-08-26 Farmaceutický prípravok obsahujúci tolterodin s regulovaným uvoľňovaním
MYPI99003665A MY127946A (en) 1998-08-27 1999-08-26 Therapeutic formulation for administering tolterodine with controlled release
CZ20001924A CZ302630B6 (cs) 1998-08-27 1999-08-26 Farmaceutický prostredek obsahující tolterodin nebo tolterodinu príbuznou slouceninu
IL15641499A IL156414A0 (en) 1998-08-27 1999-08-26 Therapeutic formulation for administering tolterodine with controlled release
NZ504618A NZ504618A (en) 1998-08-27 1999-08-26 Controlled release therapeutic formulation for administering tolterodine maintaining a constant serum level
AT99946521T ATE487471T1 (de) 1998-08-27 1999-08-26 Therapeutische formulierung zur verabreichung von tolterodin mit kontrollierter freisetzung
HU0100437A HUP0100437A3 (en) 1998-08-27 1999-08-26 Therapeutic formulation for administering tolterodine with controlled release
IL13629499A IL136294A (en) 1998-08-27 1999-08-26 Use of toltrodine, 5-hydroxy methyl metabolite or its resmat in the preparation of drugs for the treatment of unstable or overactive bladder
ARP990104280A AR029311A1 (es) 1998-08-27 1999-08-26 UN MÉTODO PARA EL TRATAMIENTO DE LA VEJIGA URINARIA INESTABLE O HIPERACTIVA CON UNA FORMULACIoN DE LIBERACIoN CONTROLADA DE TOLTERODINA O COMPUESTOS RELACIONADOS; DICHA FORMULACIoN FARMACÉUTICA Y USO DE TOLTERODINA O DE COMPUESTOS RELACIONADOS.
EP09173927A EP2153825A1 (de) 1998-08-27 1999-08-26 Therapeutische Formulierung zur Verabreichung von Tolterodin mit kontrollierter Freisetzung
TR2000/01998T TR200001998T1 (tr) 1998-08-27 1999-08-26 Kontrollü salıverilen tolterodin uygulamak için ilaç formülasyonu
DE69942928T DE69942928D1 (de) 1998-08-27 1999-08-26 Therapeutische formulierung zur verabreichung von tolterodin mit kontrollierter freisetzung
APAP/P/2001/002166A AP1323A (en) 1998-11-11 1999-11-11 New controlled release bead, a method of producing the same and multiple unit formulation comprising it.
SI9930411T SI1128819T1 (en) 1998-11-11 1999-11-11 New controlled release bead, a method of producing the same and multiple unit formulation comprising it
BRPI9915142A BRPI9915142B8 (pt) 1998-11-11 1999-11-11 novo material farmacêutico no formato de pérolas com liberação controlada, respectivo método de produção e formulação de múltiplas inidades compreendendo o mesmo
CZ20011627A CZ299582B6 (cs) 1998-11-11 1999-11-11 Nové kulicky s rízeným uvolnováním, zpusob jejichprípravy a prostredek ve forme vetšího poctu jednotek, který je obsahuje
KR10-2001-7005879A KR100467384B1 (ko) 1998-11-11 1999-11-11 신규한 방출 조절된 비이드, 이의 제조 방법 및 이를포함한 다중 유닛 제형
EP99971702A EP1128819B1 (de) 1998-11-11 1999-11-11 Neue kügelchen mit kontrollierter freisetzung, ein verfahren zu deren herstellung und diese enthaltende formulierung des typs "multiple unit"
YUP-331/01A RS49891B (sr) 1998-11-11 1999-11-11 Nove perle sa kontrolisanim oslobadjanjem, postupak za njihovu proizvodnju i višestruka jedinična formulacija koja ih sadrži
DE69910604T DE69910604T2 (de) 1998-11-11 1999-11-11 Neue kügelchen mit kontrollierter freisetzung, ein verfahren zu deren herstellung und diese enthaltende formulierung des typs "multiple unit"
CA002350061A CA2350061C (en) 1998-11-11 1999-11-11 New controlled release bead, a method of producing the same and multiple unit formulation comprising it
EEP200100254A EE05232B1 (et) 1998-11-11 1999-11-11 Reguleeritud vabastamisega graanul, meetod selle valmistamiseks ning seda sisaldav mitmehikuline ravimvorm
GEAP19995939A GEP20022833B (en) 1998-11-11 1999-11-11 New Controlled Release Bead, Method of Producing the Same and Multiple Unit Formulation Comprising It
ES99971702T ES2204193T3 (es) 1998-11-11 1999-11-11 Nueva perla de liberacion controlada, un metodo para su produccion y formulacion de multiples unidades que la contiene.
SK625-2001A SK284758B6 (sk) 1998-11-11 1999-11-11 Perlička s regulovaným uvoľňovaním, spôsob jej výroby, viacjednotkový prípravok s jej obsahom a jej použitie
PL99348612A PL195780B1 (pl) 1998-11-11 1999-11-11 Kuleczka o kontrolowanym uwalnianiu, sposób wytwarzania kuleczki, zawierająca je kapsułka i tabletka oraz zastosowanie kuleczek
IL14280999A IL142809A0 (en) 1998-11-11 1999-11-11 New controlled release bead, a method of producing the same and multiple unit formulation comprising it
OA1200100112A OA11673A (en) 1998-11-11 1999-11-11 New controlled release bead, a method of producingthe same and multiple unit formulation comprising it.
EA200100538A EA005074B1 (ru) 1998-11-11 1999-11-11 Гранула с контролируемым высвобождением, способ ее изготовления и включающая ее композиция из множества единиц
UA2001042824A UA57165C2 (uk) 1998-11-11 1999-11-11 Кулька з регульованим вивільненням, спосіб її виготовлення, багатоодинична композиція та способи лікування
CNB998132160A CN1169522C (zh) 1998-11-11 1999-11-11 新颖的控释珠粒、其制备方法和包含它的多单位制剂
NZ511430A NZ511430A (en) 1998-11-11 1999-11-11 Controlled release bead of up to four layers where a thick layer of a water-insoluble polymer has been applied to an inert core as a sealcoat
AU14366/00A AU762410B2 (en) 1998-11-11 1999-11-11 New controlled release bead, a method of producing the same and multiple unit formulation comprising it
MYPI99004911A MY122195A (en) 1998-11-11 1999-11-11 New controlled release bead, a method of producing the same and multiple unit formulation comprising it
AT99971702T ATE247458T1 (de) 1998-11-11 1999-11-11 NEUE KÜGELCHEN MIT KONTROLLIERTER FREISETZUNG, EIN VERFAHREN ZU DEREN HERSTELLUNG UND DIESE ENTHALTENDE FORMULIERUNG DES TYPS ßMULTIPLE UNITß
ARP990105734A AR027815A1 (es) 1998-11-11 1999-11-11 Formulacion farmaceutica y metodo para su produccion
PCT/SE1999/002052 WO2000027364A1 (en) 1998-11-11 1999-11-11 New controlled release bead, a method of producing the same and multiple unit formulation comprising it
PT99971702T PT1128819E (pt) 1998-11-11 1999-11-11 Nova perola de libertacao controlada um metodo para produzir a mesma e uma formulacao de unidades multiplas que a compreende
US09/763,281 US6911217B1 (en) 1998-11-11 1999-11-11 Controlled release bead, a method of producing the same and multiple unit formulation comprising it
DK99971702T DK1128819T3 (da) 1998-11-11 1999-11-11 Ny kugle til styret frigivelse, fremgangsmåde til dens fremstilling og formulering med flere enheder indeholdende denne
HU0105038A HU226582B1 (en) 1998-11-11 1999-11-11 New controlled release bead, a method of producing the same and multiple unit formulation comprising it
JP2000580595A JP3616011B2 (ja) 1998-11-11 1999-11-11 新規制御放出ビーズ、その製造方法、およびそれを含む多重ユニット製剤
IDW00200101038A ID30039A (id) 1998-11-11 1999-11-11 Manik-manik baru farmasi pelepasan terkontrol metode pembuatannya dan formulasi berbagai unit yang mengandungnya
TW089102338A TWI222879B (en) 1998-11-11 2000-02-11 Release-controlled pharmaceutical compositions for treating dysfunction of urinary bladder
TW089102332A TWI267385B (en) 1998-11-11 2000-02-11 Controlled release bead, pharmaceutical formulation comprising the same and production thereof
BG104476A BG65168B1 (bg) 1998-08-27 2000-05-26 Фармацевтична форма на толтеродин с контролирано освобождаване
NO20002977A NO329830B1 (no) 1998-08-27 2000-06-09 Oral farmasoytisk formulering inneholdende tolterodin og med kontrollert frigivelse
IS5537A IS2976B (is) 1998-08-27 2000-06-15 Lyfjablanda til inntöku um munn sem inniheldur tolteródín og hefur stýrða losun
ZA200103575A ZA200103575B (en) 1998-11-11 2001-05-03 New controlled release bead, a method of producing the same and multiple unit formulation comprising it.
IS5936A IS2370B (is) 1998-11-11 2001-05-09 Nýtt forðakyrni, aðferð við framleiðslu þess og fjöleiningablanda sem inniheldur það
NO20012314A NO331399B1 (no) 1998-11-11 2001-05-10 Kontrollert frigivelsesperle, fremgangsmate for fremstilling og multippel enhetsformulering omfattende denne og anvendelse derav
HR20010333A HRP20010333B1 (en) 1998-11-11 2001-05-10 New controlled release bead, a method of producing the same and multiple unit formulation comprising it
BG105582A BG65149B1 (bg) 1998-11-11 2001-06-08 Перли с контролирано освобождаване, метод за получаването им и включваща ги лекарствена форма
MA26228A MA25325A1 (fr) 1998-11-11 2001-06-08 Nouvelle gelule a dosage controle, la methode de production et la formulation des unites multiples qui la contiennent.
HK01104868A HK1034664A1 (en) 1998-08-27 2001-07-12 Therapeutic formulation for administering tolterodine with controlled release
HK02102521.2A HK1040917B (zh) 1998-11-11 2002-04-04 新穎的控釋珠粒、其製備方法和包含它的多單位製劑
CY20101101027T CY1111088T1 (el) 1998-08-27 2010-11-17 Θεραπευτικη φαρμακοτεχνικη μορφη για χορηγηση τολτεροδινης με ελεγχομενη απελευθερωση

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9803871A SE9803871D0 (sv) 1998-11-11 1998-11-11 Therapeutic method and formulation

Publications (1)

Publication Number Publication Date
SE9803871D0 true SE9803871D0 (sv) 1998-11-11

Family

ID=20413266

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9803871A SE9803871D0 (sv) 1998-08-27 1998-11-11 Therapeutic method and formulation

Country Status (40)

Country Link
US (1) US6911217B1 (de)
EP (1) EP1128819B1 (de)
JP (1) JP3616011B2 (de)
KR (1) KR100467384B1 (de)
CN (1) CN1169522C (de)
AP (1) AP1323A (de)
AR (1) AR027815A1 (de)
AT (1) ATE247458T1 (de)
AU (1) AU762410B2 (de)
BG (1) BG65149B1 (de)
BR (1) BRPI9915142B8 (de)
CA (1) CA2350061C (de)
CZ (1) CZ299582B6 (de)
DE (1) DE69910604T2 (de)
DK (1) DK1128819T3 (de)
EA (1) EA005074B1 (de)
EE (1) EE05232B1 (de)
ES (1) ES2204193T3 (de)
GE (1) GEP20022833B (de)
HK (1) HK1040917B (de)
HR (1) HRP20010333B1 (de)
HU (1) HU226582B1 (de)
ID (1) ID30039A (de)
IL (1) IL142809A0 (de)
IS (1) IS2370B (de)
MA (1) MA25325A1 (de)
MY (1) MY122195A (de)
NO (1) NO331399B1 (de)
NZ (1) NZ511430A (de)
OA (1) OA11673A (de)
PL (1) PL195780B1 (de)
PT (1) PT1128819E (de)
RS (1) RS49891B (de)
SE (1) SE9803871D0 (de)
SI (1) SI1128819T1 (de)
SK (1) SK284758B6 (de)
TW (2) TWI267385B (de)
UA (1) UA57165C2 (de)
WO (1) WO2000027364A1 (de)
ZA (1) ZA200103575B (de)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0924983A4 (de) * 1996-07-19 1999-08-25 Gunnar Aberg S(-)-tolterodin in der behandlung urinärer und gastrointestinaler störungen
US8563522B2 (en) 1997-07-08 2013-10-22 The Iams Company Method of maintaining and/or attenuating a decline in quality of life
EP0957073A1 (de) * 1998-05-12 1999-11-17 Schwarz Pharma Ag 3,3-Diphenylpropylaminderivate
AU784104B2 (en) * 1999-11-11 2006-02-02 Pfizer Health Ab Pharmaceutical formulation containing tolterodine and its use
MXPA05002302A (es) * 2002-08-28 2005-06-08 Pharmacia Corp Composicion liquida oral de tolterodina.
US8168170B2 (en) 2002-10-03 2012-05-01 The Procter And Gamble Company Compositions having an inner core and at least three surrounding layers
ATE432070T1 (de) * 2003-01-22 2009-06-15 Pfizer Health Ab Herabgesetzte dosis von tolterodin zur behandlung von harnwegserkrankungen
DE10315917A1 (de) * 2003-04-08 2004-11-18 Schwarz Pharma Ag Hochreine Basen von 3,3-Diphenylpropylaminmonoestern
CA2529984C (en) 2003-06-26 2012-09-25 Isa Odidi Oral multi-functional pharmaceutical capsule preparations of proton pump inhibitors
DE602004030931D1 (de) 2003-11-04 2011-02-17 Supernus Pharmaceuticals Inc
WO2005046663A1 (en) 2003-11-04 2005-05-26 Shire Laboratories, Inc. Compositions of quaternary ammonium containing bioavailability enhancers
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US8894991B2 (en) 2003-12-19 2014-11-25 The Iams Company Canine probiotic Lactobacilli
US20050152884A1 (en) 2003-12-19 2005-07-14 The Procter & Gamble Company Canine probiotic Bifidobacteria globosum
US7785635B1 (en) 2003-12-19 2010-08-31 The Procter & Gamble Company Methods of use of probiotic lactobacilli for companion animals
US8394409B2 (en) * 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
EP1629834A1 (de) † 2004-08-27 2006-03-01 KRKA, D.D., Novo Mesto Pharmazeutische Zusammensetzung von Tolterodin mit verzögerter Freisetzung
US20060194876A1 (en) * 2005-01-10 2006-08-31 Kovacs Laszlo Z Substantially pure tolterodine tartrate and process for preparing thereof
WO2006130188A1 (en) 2005-05-31 2006-12-07 The Iams Company Feline probiotic bifidobacteria
EP2270131A1 (de) 2005-05-31 2011-01-05 The Iams Company Probiotische Katzen-Laktobazillen
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
ES2559678T3 (es) 2006-01-18 2016-02-15 Intec Pharma Ltd. Método para formar dispositivos de suministro para la vía oral de un agente
PL3095447T3 (pl) 2006-02-03 2022-02-14 Opko Renal, Llc Leczenie niedoboru lub deficytu witaminy d 25-hydroksywitaminą d2 i 25- hydroksywitaminą d3
KR100714058B1 (ko) * 2006-02-06 2007-05-02 한국유나이티드제약 주식회사 톨테로딘 엘-주석산염의 서방형 경구투여 조성물 및 이의 제조 방법
BRPI0621397A2 (pt) * 2006-02-24 2012-04-17 Teva Pharma tabletes de liberação prolongada de metoprolol succinato e seus processos de preparação
MX2008011952A (es) * 2006-03-21 2008-10-01 Teva Pharma Formulacion de liberacion controlad de tolterodina.
EP1839649A1 (de) * 2006-03-31 2007-10-03 LEK Pharmaceuticals D.D. Beschichtete Formulierung von Tolterodine
CN104825397A (zh) * 2006-04-03 2015-08-12 伊萨·奥迪迪 含有机溶胶涂层的受控释放递送物件
WO2007122015A1 (en) * 2006-04-21 2007-11-01 Synthon B.V. Tolterodine beads
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
EP2026766A1 (de) 2006-05-17 2009-02-25 Synthon B.V. Tabletten-zusammensetzung mit verlängerter freisetzung von tamsulosin
SI2037936T1 (sl) 2006-06-21 2014-11-28 Opko Renal, Llc Postopek zdravljenja in prepreäśevanja sekundarnega hiperparatiroidizma
JP2008007458A (ja) * 2006-06-29 2008-01-17 Freunt Ind Co Ltd レイヤリング用核粒子とその製造方法
CA2670636A1 (en) 2006-11-27 2008-06-05 H. Lundbeck A/S Heteroaryl amide derivatives
RU2436581C2 (ru) 2007-02-01 2011-12-20 Дзе Иамс Компани Способ уменьшения воспаления и снижения стресса у млекопитающего
EP2148683A4 (de) 2007-04-25 2012-09-12 Proventiv Therapeutics Llc Verfahren zur sicheren und wirksamen behandlung und prävention von sekundärer hyperparathyreose bei chronischer nierenerkrankung
ES2403107T3 (es) 2007-04-25 2013-05-14 Cytochroma Inc. Método de tratamiento de insuficiencia y deficiencia de vitamina D
DK2148661T3 (da) 2007-04-25 2013-03-25 Cytochroma Inc Orale præparater med kontrolleret afgivelse omfattende vitamin D-forbindelse og voksagtig bærer
EP2173329A1 (de) * 2007-07-03 2010-04-14 Synthon B.V. Tolterodinkügelchen
US8110226B2 (en) * 2007-07-20 2012-02-07 Mylan Pharmaceuticals Inc. Drug formulations having inert sealed cores
US8486452B2 (en) 2007-07-20 2013-07-16 Mylan Pharmaceuticals Inc. Stabilized tolterodine tartrate formulations
WO2009019599A2 (en) * 2007-08-08 2009-02-12 Themis Laboratories Private Limited Extended release compositions comprising tolterodine
CN101801350A (zh) 2007-08-13 2010-08-11 阿巴斯迪特宁医药有限公司 抗滥用药物、使用方法和制备方法
US20090192228A1 (en) * 2008-01-28 2009-07-30 Actavis Group Ptc Ehf Controlled-Release Tolterodine Compositions and Methods
US20090214665A1 (en) * 2008-02-26 2009-08-27 Lai Felix S Controlled Release Muscarinic Receptor Antagonist Formulation
CA2629099A1 (en) * 2008-04-01 2009-10-01 Pharmascience Inc. Novel oral controlled release pharmaceutical formulations
CA2714996C (en) 2008-04-02 2020-04-07 Cytochroma Inc. Methods, compositions, uses, and kits useful for vitamin d deficiency and related disorders
US20090311317A1 (en) * 2008-05-14 2009-12-17 Capricorn Pharma Inc. Modified release tolterodine formulations
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
US8465770B2 (en) 2008-12-24 2013-06-18 Synthon Bv Low dose controlled release tablet
US9078830B2 (en) 2009-07-31 2015-07-14 Ranbaxy Laboratories Limited Multi-layered, multiple unit pharmaceutical compositions
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
WO2011061616A2 (en) 2009-11-23 2011-05-26 Micro Labs Limited Extended release compositions containing tolterodine and process for preparing the same
WO2011095388A1 (en) 2010-02-04 2011-08-11 Synthon Bv Tolterodine bead
PT2552484T (pt) 2010-03-29 2020-04-03 Opko Ireland Global Holdings Ltd Métodos e composições para redução dos níveis de parafróides
NZ706991A (en) 2010-03-29 2016-08-26 Ferring Bv A fast dissolving pharmaceutical composition
JO3112B1 (ar) 2010-03-29 2017-09-20 Ferring Bv تركيبة دوائية سريعة التحلل
CA2796877A1 (en) 2010-04-30 2011-11-03 Merck Sharp & Dohme Corp. Novel beta 3 adrenergic receptor agonists
US20120040008A1 (en) * 2010-08-11 2012-02-16 Ashish Chatterji Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
WO2012154770A1 (en) 2011-05-10 2012-11-15 Theravida, Inc. Combinations of tolterodine and salivary stimulants for the treatment of overactive bladder
GR1007628B (el) 2011-07-27 2012-06-29 Φαρματεν Αβεε, Φαρμακευτικο σκευασμα περιεχον εναν αντιμουσκαρινικο παραγοντα και μεθοδος για την παρασκευη αυτου
KR20140061438A (ko) 2011-09-16 2014-05-21 훼링 비.브이. 속용성 약학 조성물
JP5553132B2 (ja) * 2011-09-30 2014-07-16 アステラス製薬株式会社 粒子状医薬組成物
EP2872177B1 (de) 2012-07-12 2017-12-20 Ferring BV Diclofenac-formulierungen
MX2015003658A (es) * 2012-09-20 2015-09-25 Ohr Pharma Llc Microparticulas biodegradables de capas multiples para la liberacion sostenida de agentes terapeuticos.
US20150306170A1 (en) * 2012-11-21 2015-10-29 Ferring B.V. Composition for immediate and extended release
TW201422254A (zh) 2012-11-21 2014-06-16 Ferring Bv 用於速釋及延釋的組成物
NZ629598A (en) * 2013-03-13 2016-10-28 Advanced Bionutrition Corp Stable bioactive substances and methods of making
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
US20140275038A1 (en) 2013-03-15 2014-09-18 Inspirion Delivery Technologies, Llc Abuse deterrent compositions and methods of use
AU2014246617A1 (en) 2013-12-23 2015-07-09 Sun Pharmaceutical Industries Limited Multi-layered, multiple unit pharmaceutical compositions
CR20170085A (es) 2014-08-07 2017-04-25 Opko Ireland Global Holdings Ltd Terapia adjuntiva con 25-hidroxi vitamina d
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
CA2936740C (en) * 2014-10-31 2017-10-10 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
EP3431107A4 (de) * 2016-02-23 2019-11-13 Nipro Corporation Partikel einer pharmazeutischen zusammensetzung und im mund zerfallende zubereitung damit
BR112018069727A2 (pt) 2016-03-28 2019-02-05 Opko Ireland Global Holdings Ltd métodos de tratamento com vitamina d

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1144911B (it) 1981-03-19 1986-10-29 Pharmatec Spa Composizione farmaceutica a rilascio controllato contenente ibuprofen
JPH07107450A (ja) 1993-10-08 1995-04-21 Hitachi Ltd 情報通信装置
JP3453186B2 (ja) 1994-04-14 2003-10-06 共和薬品工業株式会社 徐放性マイクロカプセルおよびその製造方法
SE9402422D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New beads for controlled release and a pharmaceutical preparation containing the same
US5645858A (en) * 1994-10-06 1997-07-08 Ortho Pharmaceutical Corporation Multilayered controlled release pharmaceutical dosage form
US5567441A (en) 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
EP0924983A4 (de) 1996-07-19 1999-08-25 Gunnar Aberg S(-)-tolterodin in der behandlung urinärer und gastrointestinaler störungen
US6312728B1 (en) * 1998-07-07 2001-11-06 Cascade Development, Inc. Sustained release pharmaceutical preparation

Also Published As

Publication number Publication date
JP3616011B2 (ja) 2005-02-02
BRPI9915142B1 (pt) 2015-08-25
SK6252001A3 (en) 2002-01-07
EA200100538A1 (ru) 2001-10-22
BR9915142A (pt) 2001-08-07
HRP20010333B1 (en) 2004-10-31
AU762410B2 (en) 2003-06-26
HUP0105038A2 (en) 2002-06-29
BG105582A (en) 2001-12-29
KR20010075695A (ko) 2001-08-09
HUP0105038A3 (en) 2006-07-28
DE69910604D1 (de) 2003-09-25
OA11673A (en) 2005-01-12
AP1323A (en) 2004-11-05
MY122195A (en) 2006-03-31
WO2000027364A1 (en) 2000-05-18
HK1040917B (zh) 2005-05-27
MA25325A1 (fr) 2001-12-31
NO331399B1 (no) 2011-12-19
NO20012314L (no) 2001-07-09
EP1128819B1 (de) 2003-08-20
UA57165C2 (uk) 2003-06-16
ID30039A (id) 2001-11-01
IS5936A (is) 2001-05-09
HK1040917A1 (en) 2002-06-28
BG65149B1 (bg) 2007-04-30
IS2370B (is) 2008-06-15
YU33101A (sh) 2003-10-31
CZ20011627A3 (cs) 2001-10-17
ES2204193T3 (es) 2004-04-16
PT1128819E (pt) 2003-12-31
DE69910604T2 (de) 2004-06-24
EE200100254A (et) 2002-12-16
HRP20010333A2 (en) 2003-04-30
TWI267385B (en) 2006-12-01
CN1326339A (zh) 2001-12-12
CA2350061C (en) 2005-05-17
ATE247458T1 (de) 2003-09-15
HU226582B1 (en) 2009-04-28
CZ299582B6 (cs) 2008-09-10
EE05232B1 (et) 2009-12-15
NZ511430A (en) 2003-05-30
IL142809A0 (en) 2002-03-10
CN1169522C (zh) 2004-10-06
PL348612A1 (en) 2002-06-03
AR027815A1 (es) 2003-04-16
KR100467384B1 (ko) 2005-01-24
PL195780B1 (pl) 2007-10-31
JP2003517446A (ja) 2003-05-27
BRPI9915142B8 (pt) 2021-05-25
NO20012314D0 (no) 2001-05-10
AU1436600A (en) 2000-05-29
SK284758B6 (sk) 2005-11-03
GEP20022833B (en) 2002-11-25
DK1128819T3 (da) 2003-12-01
SI1128819T1 (en) 2003-12-31
AP2001002166A0 (en) 2001-06-30
CA2350061A1 (en) 2000-05-18
RS49891B (sr) 2008-08-07
ZA200103575B (en) 2002-05-03
EA005074B1 (ru) 2004-10-28
US6911217B1 (en) 2005-06-28
EP1128819A1 (de) 2001-09-05
TWI222879B (en) 2004-11-01

Similar Documents

Publication Publication Date Title
SE9803871D0 (sv) Therapeutic method and formulation
MXPA02004574A (es) Formulacion farmaceutica que contiene tolterodina y su uso.
ME00850B (me) Nove perle sa kontrolisanim oslobađanjem, postupak za njihovu proizvodnju i višestruka jedinična formulacija koja ih sadrži
CA2193129A1 (en) Transdermal drug delivery system
MY105279A (en) Transdermal therapeutic system comprising tulobuterol as active substance.
MY106628A (en) Estrogen-containing active substance plaster
WO2002003969A3 (de) Transdermales therapeutisches system mit hochdispersem siliziumdioxid
EP0280737A4 (de) Steroidenheilmittelzubereitung zur äusserlichen verwendung.
ATE333898T1 (de) Glycerinmonolaurat und laurylacetat enthaltende mittel zur hautpenetrationsbeschleunigung
MX9704672A (es) Dispositivo surtidor de suspension de farmaco, de liberacion controlada.
NO995908L (no) Implantater for kontrollert frigivning av farmasoeytisk aktive bestanddeler samt fremgangsmåte for fremstilling derav
BR9305783A (pt) Processo para preparar grânulos dispersiveis em água e grânulos dispersíveis em água
AU2001291526A1 (en) Sustained release composition containing clarithromycin
NO942396L (no) Preparat med vedvarende frigiving av anti-endotelin substans
WO2001039752A3 (de) Transdermales therapeutisches system enthaltend leicht flüchtige wirkstoffe
WO1994025025A3 (de) Systeme zur kontrollierten abgabe von pilocarpin
DE69525938T2 (de) Antimikrobielle materialen
AU695970B2 (en) Estradiol-TTS having water-binding additives
ES2141225T3 (es) Formulacion solida para la proteccion de cultivos.
CA2366862A1 (en) Transdermal therapeutic system and process for its production
PL332035A1 (en) Transdermal therapeutic system including an estriol-containing composition of active substances
CA2197867A1 (en) Oestradiol transdermal therapeutic system comprising hygroscopic additives